{"id":"signifor-pasireotide","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hyperglycemia"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Abdominal pain"},{"rate":"15-25","effect":"Nausea"},{"rate":"15-20","effect":"Cholelithiasis"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pasireotide acts as a multi-receptor somatostatin analog with preferential binding to somatostatin receptor subtypes 1, 3, and 5. It suppresses the secretion of growth hormone and insulin-like growth factor-1 (IGF-1) in acromegaly, and inhibits ACTH secretion in Cushing's disease. The drug also has direct antiproliferative effects on neuroendocrine tumor cells.","oneSentence":"Pasireotide is a somatostatin receptor agonist that binds to multiple somatostatin receptor subtypes to suppress hormone secretion and inhibit tumor growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:04.477Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly in patients inadequately controlled by surgery or radiotherapy, or for whom surgery/radiotherapy is not an option"},{"name":"Cushing's disease in patients for whom surgery is not an option or has failed"}]},"trialDetails":[{"nctId":"NCT06784752","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-05-30","conditions":"Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)","enrollment":240},{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":226},{"nctId":"NCT02713776","phase":"PHASE2","title":"Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-12-13","conditions":"Enterostomy","enrollment":57},{"nctId":"NCT01313559","phase":"PHASE2","title":"Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-06","conditions":"Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer","enrollment":6},{"nctId":"NCT06456359","phase":"PHASE2","title":"Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2024-12-19","conditions":"Desmoplastic Small Round Cell Tumor, Synovial Sarcoma","enrollment":28},{"nctId":"NCT02310269","phase":"","title":"Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease","status":"COMPLETED","sponsor":"RECORDATI GROUP","startDate":"2013-03-28","conditions":"Cushings Disease","enrollment":152},{"nctId":"NCT01794793","phase":"PHASE4","title":"Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies","status":"COMPLETED","sponsor":"RECORDATI GROUP","startDate":"2013-06-10","conditions":"Cushing's Disease, Acromegaly, Neuroendocrine Tumors","enrollment":337},{"nctId":"NCT01253161","phase":"PHASE2","title":"Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-02-01","conditions":"Neuroendocrine Tumors, Carcinoid Tumors","enrollment":29},{"nctId":"NCT02835131","phase":"","title":"Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia","status":"NO_LONGER_AVAILABLE","sponsor":"Montefiore Medical Center","startDate":"","conditions":"Congenital Hyperinsulinism","enrollment":""},{"nctId":"NCT03103009","phase":"PHASE1","title":"Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-03-22","conditions":"Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia","enrollment":1},{"nctId":"NCT00171730","phase":"PHASE2","title":"An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-08-24","conditions":"Acromegaly","enrollment":30},{"nctId":"NCT00171951","phase":"PHASE2","title":"Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-08-13","conditions":"Cushing Disease","enrollment":19},{"nctId":"NCT03053284","phase":"PHASE2","title":"Pasireotide in Hyperinsulinemic Hypoglycemia","status":"WITHDRAWN","sponsor":"Montefiore Medical Center","startDate":"2017-04","conditions":"Congenital Hyperinsulinism, Insulinoma, Hyperinsulinism","enrollment":""},{"nctId":"NCT02749227","phase":"PHASE2","title":"Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors","status":"TERMINATED","sponsor":"Columbia University","startDate":"2017-07-10","conditions":"Pituitary Tumor, ACTH-producing Pituitary Tumour","enrollment":4},{"nctId":"NCT01563354","phase":"PHASE2","title":"3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08-16","conditions":"Neuroendocrine Carcinoma of the Lung and Thymus","enrollment":124},{"nctId":"NCT01468532","phase":"PHASE1, PHASE2","title":"Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2011-10","conditions":"Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer","enrollment":18},{"nctId":"NCT01270321","phase":"PHASE2","title":"Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-11","conditions":"Thyroid Cancer","enrollment":42},{"nctId":"NCT02619617","phase":"PHASE2","title":"Safety and Efficacy Study of SOM230 s.c. in Cluster Headache","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-10-31","conditions":"Cluster Headache - Episodic and Chronic","enrollment":28},{"nctId":"NCT01263353","phase":"PHASE1","title":"Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":"Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System","enrollment":36},{"nctId":"NCT01652547","phase":"PHASE1","title":"A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Metastatic Melanoma and Merkel Cell Carcinoma","enrollment":10},{"nctId":"NCT00698464","phase":"PHASE1","title":"Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07","conditions":"Hepatic Cirrhosis, Alcoholism","enrollment":34},{"nctId":"NCT01646684","phase":"PHASE1","title":"Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-08","conditions":"Castration Resistant Prostate Cancer","enrollment":9},{"nctId":"NCT01578928","phase":"PHASE1","title":"A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Renal Impairment","enrollment":50},{"nctId":"NCT00446082","phase":"PHASE1","title":"Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-06","conditions":"Carcinoid Tumor, Acromegaly","enrollment":85},{"nctId":"NCT01364415","phase":"PHASE1","title":"Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08","conditions":"Neuroendocrine Tumors","enrollment":29},{"nctId":"NCT01385956","phase":"PHASE1","title":"SOM 230 and Gemcitabine in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-06","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT01670110","phase":"PHASE2","title":"Pasireotide LAR in Severe Polycystic Liver Disease","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-08","conditions":"Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease","enrollment":48},{"nctId":"NCT02354508","phase":"PHASE3","title":"Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-03-31","conditions":"Acromegaly","enrollment":123},{"nctId":"NCT01673646","phase":"PHASE2","title":"Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10-16","conditions":"Acromegaly, Pituitary Gigantism","enrollment":33},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT01590199","phase":"PHASE1","title":"Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05-18","conditions":"Neuroendocrine Tumors","enrollment":18},{"nctId":"NCT01469572","phase":"PHASE1","title":"Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-12","conditions":"Neuroendocrine Tumors","enrollment":13},{"nctId":"NCT03514576","phase":"PHASE4","title":"Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery","status":"UNKNOWN","sponsor":"Zealand University Hospital","startDate":"2018-06-01","conditions":"Hypoglycemia, Reactive","enrollment":5},{"nctId":"NCT01582061","phase":"PHASE3","title":"An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-16","conditions":"Cushing's Disease","enrollment":104},{"nctId":"NCT01374906","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11-04","conditions":"Cushing's Disease","enrollment":150},{"nctId":"NCT01137682","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-07-19","conditions":"Acromegaly","enrollment":198},{"nctId":"NCT02527993","phase":"PHASE4","title":"Treatment of Hypoglycemia Following Gastric Bypass Surgery","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2015-10","conditions":"Hypoglycemia, Obesity, Surgery","enrollment":11},{"nctId":"NCT02021942","phase":"PHASE2","title":"Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size","status":"COMPLETED","sponsor":"Prof. Dr. Berthold Schalke","startDate":"2012-03","conditions":"Primary Inoperable Thymoma, Local Recurrent Thymoma","enrollment":16},{"nctId":"NCT02780882","phase":"PHASE2","title":"SOM230 Ectopic ACTH-producing Tumors","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2015-12","conditions":"Ectopic ACTH Syndrome","enrollment":""},{"nctId":"NCT01372618","phase":"PHASE1, PHASE2","title":"Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2011-06","conditions":"Ductal Carcinoma in Situ","enrollment":9},{"nctId":"NCT00929669","phase":"PHASE2","title":"Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2009-06","conditions":"Gonadotroph Adenomas","enrollment":2},{"nctId":"NCT01252251","phase":"PHASE2","title":"RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-11","conditions":"Uveal Melanoma","enrollment":14},{"nctId":"NCT01639352","phase":"PHASE2","title":"Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Lynn Feun","startDate":"2012-07","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT00600886","phase":"PHASE3","title":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-02-11","conditions":"Acromegaly","enrollment":358},{"nctId":"NCT01637272","phase":"PHASE2","title":"Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-08","conditions":"Dumping Syndrome","enrollment":43},{"nctId":"NCT01374451","phase":"PHASE2","title":"Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-06","conditions":"Islet Cell Tumor","enrollment":160},{"nctId":"NCT01372644","phase":"PHASE1","title":"Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2007-11","conditions":"Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast","enrollment":15},{"nctId":"NCT00088582","phase":"PHASE2","title":"Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-03","conditions":"Acromegaly","enrollment":62},{"nctId":"NCT00088608","phase":"PHASE2","title":"A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-04","conditions":"Cushing's Syndrome","enrollment":26},{"nctId":"NCT01617733","phase":"PHASE2","title":"Pasireotide Therapy in Patients With Nelson's Syndrome","status":"TERMINATED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2011-03","conditions":"Nelson Syndrome","enrollment":8},{"nctId":"NCT00804336","phase":"PHASE1","title":"Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2008-10","conditions":"Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor","enrollment":22},{"nctId":"NCT01620138","phase":"PHASE2, PHASE3","title":"Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2010-03","conditions":"Non-functioning Pituitary Adenomas, Prolactinomas","enrollment":21},{"nctId":"NCT02668172","phase":"PHASE4","title":"Pasireotide LAR and Pegvisomant Study in Acromegaly","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2015-08","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT00958841","phase":"PHASE2","title":"Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome","enrollment":118},{"nctId":"NCT01625520","phase":"PHASE2","title":"SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"Federico II University","startDate":"2012-02","conditions":"Medullary Thyroid Cancer","enrollment":19},{"nctId":"NCT01488487","phase":"PHASE2","title":"Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2011-12","conditions":"Advanced Adult Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT00434148","phase":"PHASE3","title":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Cushing's Disease","enrollment":162},{"nctId":"NCT01329289","phase":"PHASE2","title":"SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2011-12","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma","enrollment":""},{"nctId":"NCT00994110","phase":"PHASE3","title":"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-10","conditions":"Pancreatic Cancer","enrollment":439},{"nctId":"NCT01995734","phase":"","title":"An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly","status":"APPROVED_FOR_MARKETING","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Acromegaly","enrollment":""},{"nctId":"NCT01434069","phase":"PHASE1","title":"Phase I Trial of Combination of FOLFIRI and SOM 230","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-09","conditions":"Gastrointestinal Tumor","enrollment":16},{"nctId":"NCT01128192","phase":"PHASE2","title":"Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Robert R. Henry, MD","startDate":"2009-08","conditions":"Hyperglycemia","enrollment":45},{"nctId":"NCT00813592","phase":"PHASE2","title":"Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-11","conditions":"Cancer","enrollment":2},{"nctId":"NCT00690430","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Symptomatic Refractory Resistant Carcinoid Disease","enrollment":186},{"nctId":"NCT01895296","phase":"PHASE2","title":"Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2008-09","conditions":"Postoperative Dumping Syndrome","enrollment":9},{"nctId":"NCT01234974","phase":"PHASE2","title":"IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2010-12","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT00088595","phase":"PHASE2","title":"Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-01","conditions":"Carcinoid Tumors","enrollment":45},{"nctId":"NCT01417806","phase":"PHASE2","title":"Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"South Florida Veterans Affairs Foundation for Research and Education","startDate":"2011-07","conditions":"Small Cell Lung Cancer","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Signifor"],"phase":"marketed","status":"active","brandName":"Signifor (pasireotide)","genericName":"Signifor (pasireotide)","companyName":"Zealand University Hospital","companyId":"zealand-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pasireotide, also known as Signifor, is used to treat conditions such as Acromegaly, Somatostatin Receptor Positive (SSTR+) tumors, and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). It works by targeting the somatostatin receptors SSTR2, SSTR3, and SSTR5.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2012-04-24T00:00:00.000Z","mah":"Recordati Rare Diseases","brand_name_local":"Signifor","application_number":"EMEA/H/C/002052"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-12-14T00:00:00.000Z","mah":"RECORDATI RARE","brand_name_local":"SIGNIFOR","application_number":"NDA200677"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}